Resmed (RSMDF) Cash & Equivalents (2009 - 2026)

Resmed (RSMDF) has reported Cash & Equivalents for 18 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 21.48% year-over-year to $1.5 billion; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (up 21.48% YoY), and the FY2026 full-year result was $1.5 billion, up 21.48% from the prior year.
• Cash & Equivalents fell to $1.5 billion in Q2 2026 per RSMDF's latest filing, from $1.7 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.7 billion in Q1 2026 and bottomed at $201.8 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $628.2 million across 5 years, with a median of $263.5 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slipped 24.98% in 2022, then jumped 407.4% in 2025.
• Over 5 years, Cash & Equivalents stood at $253.2 million in 2022, then declined by 16.96% to $210.2 million in 2023, then surged by 148.25% to $521.9 million in 2024, then jumped by 171.5% to $1.4 billion in 2025, then grew by 3.68% to $1.5 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.5 billion, $1.7 billion, and $1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.